Journal of International Psychiatry

[Abstract] Objective: to analyze the clinical effect and safety of olanzapine and amisulpride in the treatment of refractory schizophrenia. Methods: 102 patients with refractory schizophrenia in our hospital from September 2018 to September 2020 were selected and divided into two groups by single blind random sampling method. 51 patients in the control group were treated with olanzapine, and 51 patients in the experimental group were treated with olanzapine and amisulpride. The clinical efficacy, PANSS score, neurotrophic factor index, serum inflammatory factors and adverse reactions were compared between the two groups Rate. Results: the clinical total effective rate of the experimental group (96.08%) was higher than that of the control group (74.51%). After treatment, the serum GDNF and BDNF levels of the experimental group were higher than those of the control group, and the serum IL-6, IL-1 β, TGF - β 1 factor and PANSS score of the experimental group after treatment were lower than those of the control group (P<0.05). The incidence of adverse reactions in the experimental group (5.88%) was higher than that in the control group (7.84%), P > 0.05. Conclusion: Olanzapine and amisulpride can effectively improve the mental symptoms and neurological function of patients with refractory schizophrenia, reduce inflammatory reaction, and have fewer adverse reactions, which is worthy of reference.

[Key words] olanzapine; amisulpride; refractory schizophrenia; clinical effect; safety